About Fractalkine
Fractalkine (CX3CL1) is a protein
from Homo sapiens identified by UniProt accession
P78423, 397 residues long.
MolForge cross-references it against 0 known binders and
623 disease associations.
Target properties
| Protein name | Fractalkine |
|---|
| UniProt accession | P78423 |
|---|
| Gene | CX3CL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 397 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (623)
Diseases linked to this target (Open Targets).
- CX3CL1 measurement · score 0.37
- blood protein measurement · score 0.32
- eosinophil count · score 0.30
- glioblastoma multiforme · score 0.26
- neurodegenerative disease · score 0.18
- breast adenocarcinoma · score 0.17
- head and neck squamous cell carcinoma · score 0.16
- hemoglobin measurement · score 0.14
- hematocrit · score 0.14
- red blood cell density measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P78423-F1 | alphafold | PREDICTED | 55.92 | — |
Amino-acid sequence (397 residues)
MAPISLSWLL RLATFCHLTV LLAGQHHGVT KCNITCSKMT SKIPVALLIH YQQNQASCGK RAIILETRQH RLFCADPKEQ WVKDAMQHLD RQAAALTRNG GTFEKQIGEV KPRTTPAAGG MDESVVLEPE ATGESSSLEP TPSSQEAQRA LGTSPELPTG VTGSSGTRLP PTPKAQDGGP VGTELFRVPP VSTAATWQSS APHQPGPSLW AEAKTSEAPS TQDPSTQAST ASSPAPEENA PSEGQRVWGQ GQSPRPENSL EREEMGPVPA HTDAFQDWGP GSMAHVSVVP VSSEGTPSRE PVASGSWTPK AEEPIHATMD PQRLGVLITP VPDAQAATRR QAVGLLAFLG LLFCLGVAMF TYQSLQGCPR KMAGEMAEGL RYIPRSCGSN SYVLVPV
Explore Fractalkine with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets